PAST TOP PICK
(A Top Pick Nov 12/19, Up 9%) Very stable, defensive income stock. Plan to increase dividend annually by 5% until 2025, and they have the capital to do so. Visible dividend growth, with a 47-year track record. Yield around 3.8%.
PAST TOP PICK
(A Top Pick Nov 12/19, Up 13%) Just under 40% of revenues come from emerging markets, and this will continue to grow. During the pandemic, they've seen stronger growth in their belt market, as people are doing more snacking at home. Trades at a discount to peers, and this gap should narrow over time.
PAST TOP PICK
(A Top Pick Nov 12/19, Up 6%) Big presence in China, and there's lots of potential there. Also in India and European markets, and you want this exposure to markets not fully developed. Recently bought a new brand, which they can grow and franchise out.
HOLD
Retail pharma and health insurance. Reported a pretty good quarter. Attractive multiple, still single digits. Healthcare reform was an overhang, but the divided Congress may dampen that reform. Earnings multiple should expand, and stock should do well in foreseeable future.
BUY
A good income name. She usually holds 2.5-3% of a portfolio in each name for income. Maintained pre-Covid guidance. Question is do they bring on projects or do share buybacks? Highly defensible business, long-term contracts. Yields over 8%.
DON'T BUY

Doesn't hold producers, as oil price not favourable, especially in western Canada. SU doesn't qualify as an income stock, as cashflow of producers is predicated on the commodity price, which can be difficulty to forecast and may trend down. Prefers, and holds, ENB instead.

COMMENT

You could own it if you want direct property exposure. She owns BAM instead, which owns 50-60% of BPY, as she likes the whole stable. Dividend should be safe. Going through a difficult time with retail. Will take a while to work through, but they'll do it. Commercial and retail properties are Class A, well located. Experienced management.

WATCH
Looks more interesting with the potential acquisition of RSA, as it expands their growth potential. Excellent operators. P&C insurance gets repriced annually, a plus. She's planning to research it more closely.
BUY ON WEAKNESS
Likes the group as a whole. Level of loss provisions has peaked. US economy has improved faster than thought, a good sign. In Canada, financial assistance has helped on the mortgage side. Watch as mortgage moratorium ends. Yields are attractive, but not allowed to increase this year. Attractive valuation. Hold, and buy on weak days like today.
BUY ON WEAKNESS
Likes cloud growth and recurring revenue. Wait for a 5-10% pullback to start a position. Likes its positioning for the long-term.
DON'T BUY
Tremendous performer through the pandemic. Huge multiples, doesn't make money, huge expectations on the stock. 1/3 of client base is small business, and the retention rate is very low. Pandemic has given it momentum. Competing products out there. Wouldn't buy it here.
TOP PICK
Long-term growth. #1 with a 17% global share. Service contract side is very attractive, with very high margins. Service accounts for 57% of revenue, but 80% of profit. High renewal rate, long contracts. Defensive cashflow, more recession-resistant. Great upgrade cycle coming up. Yield is 1.21%. (Analysts’ price target is $69.30)
TOP PICK
Benefits from secular trend to plastic. Revenues and earnings were down, when typically these grow. Transaction volume was down, but this will return when the economy recovers. (Analysts’ price target is $221.09)
TOP PICK
Global design and engineering. Organic and acquisition growth. Lots of dry powder to put to work for M&As. Well positioned in transportation infrastructure in the US, a natural beneficiary of government stimulus. Yield is 1.69%. (Analysts’ price target is $99.15)